



For additional information contact:
Jody Donohue, APR
Communications Manager
Office: 913.945.4405
Mobile: 913.333.6329
Email: jody.donohue@ceva.com

Ceva Animal Health posts strong double-digit growth again in 2014

(Libourne, France – March 5, 2015) Consolidated sales of the Ceva Group reached €766m at the end of 2014, representing growth of 23% and +14.1% at a constant perimeter and exchange rates. Sales grew in all zones and across all species with particularly strong performance being recorded in companion animals (+17.3%) and poultry (+14%).

The group delivered an operational result slightly ahead of the budgeted objective but also continued to make significant investment in R&D where spending exceeded 9% of sales. The integration of Sogeval proved to be a major success with the creation of a new Ceva Sogeval campus in Laval, France and significant growth in sales (+21%) in France of the joint business.

Marc Prikazsky, Ceva's Chairman and CEO commented, "The consistency in our performance is particularly pleasing and stems from our innovative pipeline of products that should continue to drive growth in the years ahead. I'm delighted by the way we were able to integrate Sogeval into the group, with minimal disruption and indeed a very strong result in France."

###

About Ceva Animal Health: Ceva is a world-wide leader in the development and production of poultry vaccines including both vector and custom vaccines to combat health issues such as Salmonella, Newcastle Disease, Marek's Disease, Fowl Pox, Gumboro, Infectious Laryngotrachitis, Avian Influenza, Avian Encephalomyelitis and Mycoplasma Gallisepticum. Ceva currently supplies more than 50 countries with critical poultry vaccines from the company's North American headquarters located in Lenexa, Kansas. To learn more visit www.ceva.us.